Karmanos Now Offers FDA-Approved Daraxonrasib (Rasonque) for Metastatic Pancreatic Cancer

The Barbara Ann Karmanos Cancer Institute now offers daraxonrasib (Rasonque), an FDA-approved oral therapy for adults with metastatic pancreatic adenocarcinoma who have failed prior systemic therapy or are unsuitable for multiagent systemic therapy, following positive phase III trial results showing improved survival.

This Wire brief sits within Fusion42's coverage of Biotech.